Antiarrhythmic drugs with neutral survival effects, alongside ACE inhibitors, ARBs, and beta-blockers, are preferred for managing coexisting atrial fibrillation and heart failure.
This review highlights the role of antiarrhythmic drugs and standard heart failure therapies in managing concomitant atrial fibrillation and congestive heart failure.
Absolute Event Rate: 0% vs 0%
AF in Heart Failure. Atrial fibrillation and congestive heart failure are commonly occurring cardiac disorders that often exist concomitantly. The prognostic significance of the presence or absence of atrial fibrillation, as an independent risk factor, in patients with heart failure remains controversial. Antiarrhythmic drugs with good hemodynamic profiles and neutral effects on survival are preferred treatments for converting atrial fibrillation and maintaining sinus rhythm. Other standard therapies for congestive heart failure, such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and beta-blockers also have a role in the treatment of these coexisting disease states. The article presents an overview of atrial fibrillation in patients with heart failure and reviews the prevalence, prognostic significance, and efficacy of various antiarrhythmic agents for the conversion and maintenance of sinus rhythm.
Naccarelli et al. (Mon,) reported a other. Antiarrhythmic drugs with neutral survival effects, alongside ACE inhibitors, ARBs, and beta-blockers, are preferred for managing coexisting atrial fibrillation and heart failure.